Fermenta Biotech Ltd
Fermenta Biotech Ltd Q1 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q1 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Fermenta Biotech Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1-FY25 consolidated operational revenue: INR 781 million, down 5.3% YoY (Q1-FY24: INR 824 million). Q1-FY25 Consolidated Financials: - EBITDA: INR 8 Mn (down 92.7% YoY from INR 109 Mn in Q1-FY24) - EBITDA Margin: 1.02% (down from 13.26% YoY) - Profit After Tax (PAT): INR (59) Mn (loss, compa
From Fermenta Biotech Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1-FY25 consolidated operational revenue: INR 781 million, down 5.3% YoY (Q1-FY24: INR 824 million).
- Q1-FY25 standalone operational revenue: INR 727 million, down 5.3% YoY (Q1-FY24: INR 768 million).
- Vitamin D3 for Human Nutrition volumes in Q1-FY25 rose by 48% YoY compared to Q1-FY24.
- Vitamin D3 for Human Nutrition volumes were 33% lower QoQ compared to Q4-FY24.
- Average prices of Vitamin D3 for Human Nutrition were 2% higher YoY and 10% higher QoQ.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Fermenta Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹122 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech Ltd's management said in earlier quarters
- Q4 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
- Q1 FY22 earnings call →
- Q1 FY22 earnings call →
- Q3 FY21 earnings call →
- Q2 FY21 earnings call →
- Q2 FY21 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem Ltd (Q1 FY25)
Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8). Key investor presentation takeaways from NG
- Shree Ganesh Remedies Ltd (Q1 FY25)
Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore. Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY
- Themis Medicare Ltd (Q1 FY25)
122.99 Cr, up 27.26% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q1 FY25 investor presentation — and how it ranks against sector
Frequently Asked Questions
What were Fermenta Biotech Ltd Q1 FY25 results?
Q1-FY25 consolidated operational revenue: INR 781 million, down 5.3% YoY (Q1-FY24: INR 824 million). Q1-FY25 Consolidated Financials: - EBITDA: INR 8 Mn (down 92.7% YoY from INR 109 Mn in Q1-FY24) - EBITDA Margin: 1.02% (down from 13.26% YoY) - Profit After Tax (PAT): INR (59) Mn (loss, compa
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fermenta Biotech Ltd planning capital expenditure?
The presentation does not explicitly mention any details on capex, capacity expansion, new plant, or project investments including amounts, status, or timelines.
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.